DUBLIN–(BUSINESS WIRE)–The “Top 5 Generic Opportunities in Pharmaceuticals to Watch in 2019: Perspective for the Future” report has been added to ResearchAndMarkets.com’s offering.
The Report Includes:
- An overview of top five opportunities for generic or biosimilar drugs in pharmaceuticals market 2019
- Coverage of generics and discussion on their characteristics
- Information on Hatchmann-Wax act and its effect on market competitiveness impacting pricing and development of original drugs
- Insights on the key challenges and opportunities in the development of generics or biosimilar drugs
- Description of product class, mechanism of action, indications and contraindications,
- Clinical and generic development of the prominent products
- Detailed patent analysis i.e. expiry and exclusivity, regulations and policies and patent expiry and market impact
- Profiles of key competitors engaged in the development of generic and biosimilars
Key Topics Covered:
Chapter 1 Introduction
- Study Goals and Objectives
- Scope of Report
- Information Sources
- Methodology
- Analyst’s Credentials
Chapter 2 Perspectives of Generics and Biosimilar Business
- Overview of Generics and Biosimilars
- Generics
- Types of Generics
- Biosimilars
- Lifecycle of a Biosimilar Drug
- Development of a Biosimilar
- Manufacturing of a Biosimilar
- Preclinical Studies and Validation of a Biosimilar
- Clinical Trials
- Generics vs. Biosimilars
- Market Landscape of Generics and Biosimilars
- Competitive Landscape of Generics and Biosimilars
- Trends
- Structure of the Generics Industry
- Biosimilars Competitive Landscape
- Bio-intellectual Companies
- Opportunistic Companies
- Emerging Trends in Biosimilar Industry Structure
Chapter 3 Patents & Patent Cliffs
- Patents and IP
- Supplementary Protection Certificates
- Patent Regulations in Favor of Branded Biologics
- Patent Regulations in Favor of Biosimilars-Emerging Trends
Chapter 4 Regulation of Generics and Biosimilars Business
- United States
- European Union
- EU Marketing Authorization Systems
- Types of Applications
- Regulation of Biosimilars
- EU Provisions
- Evolving Situation in the U.S.
- User Fees
- Defensive Strategies by Big Pharma
- Authorized Generics
- User Fees
- Changing Climate for Generics
- Situation in Europe
Chapter 5 Product Profile Analysis
- Overview
- Profile Analysis
- Xolair
- Mechanism of Action
- Indications and Contraindication
- Dosage and Administration
- Historical Net Sales and Growth Rates of Xolair for Novartis
- Timeline of Key Events-Xolair (Omalizumab)
- Key Regulatory Approvals
- Pricing and Annual Cost of Xolair Associated with Treatment
- Factors Favoring Generic/Biosimilar Development of Xolair
- Biosimilar Clinical Developments
- Profiles Key Companies engaged in the Business/Development of Xolair and Biosimilar Omalizumab
- Companies Developing Biosimilar Version of Omalizumab
- Revlimid
- Mechanism of Action
- Indications and Contraindication
- Dosage and Administration
- Historical Net Sales and Growth Rates
- Timeline of Key Events-Revlimide (Lenalilomide)
- Pricing and Annual Cost of Revlimid Associated with Treatment
- Factors Influencing Generic Development
- Business & Legal Challenges
- FDA’s Campaign of Naming and Shaming of Branded Pharmaceuticals Adopting Anti-Trade Practices
- Revlimid Generics Development/Marketed Drugs
- Company Profiles
- Generic Manufacturers of Revlimid
- Orencia
- Mechanism of Action
- Indications and Contraindication
- Dosage and Administration
- Historical Net Sales and Growth Rates of Orencia for Bristol-Meyers Squibb
- Timeline of Key Events-Orencia
- Pricing and Annual Cost of Orencia Associated with Treatment
- Factors Favoring Generic/Biosimilar Development of Orencia
- Biosimilar Clinical Developments
- Profiles Key Companies Engaged in the Business/Development of Xolair and Biosimilar Omalizumab
- Companies Developing Biosimilar Version of Omalizumab
- Pradaxa
- Mechanism of Action
- Indications
- Adverse Reaction
- Dosage and Administration
- Historical Net Sales and Growth Rates of Pradaxa
- Clinical Development
- Timeline of Key Events-Pradaxa (Dabigatran)
- Pricing and Annual Cost of Pradaxa
- Factors Favoring Generic Development of Pradaxa
- Generics Clinical Developments
- Profiles of the Pradaxa Manufacturer
- Generic Manufacturer of Pradaxa
- Gilenya
- Mechanism of Action
- Indications
- Dosage and Administration
- Historical Net Sales and Growth Rates of Gilenya for Novartis
- Timeline of Key Events-Gilenya
- Pricing and Annual Cost of Gilenya Associated with Treatment
- Factors Favoring Generic/Biosimilar Development of Gilenya
- Generic Clinical Developments
- Profiles Key Companies Engaged in the Business/Development of Gilenya
- Companies Developing Generic Version of Gilenya
Chapter 6 Conclusion
- Improved Understanding of Pharmaceutical Technologies
- Access to Pharmaceutical Technologies and Production Methods
- Shift in the Business Model of Pharmaceutical Industry
- Challenges
- Future Perspectives
Companies Mentioned
- Novartis
For more information about this report visit https://www.researchandmarkets.com/r/g5510p
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900